top of page

Role of Inflammasome Activation in Lung Injury Highlighted at Neonatal Research Symposium

December 19, 2023


Rashmin C. Savani, MBChB, Head of Scientific Advisory Board, Azome Therapeutics, spoke on the critical role of RHAMM ((Receptor for Hyaluronan-Mediated Motility) in inflammasome activation at the 15th Annual Bowman Symposium on Neonatal Research held on November 8-9 at The Children’s Hospital Research Institute of Manitoba in Winnipeg, Canada.


Dr. Savani’s talk, ““The Pathophysiology of Lung Injury and Inflammation,” discussed the mechanisms controlling inflammation and the role of inflammasome activation in disease processes. During the symposium, he also participated in a Cardiorespiratory Research “Meet the Experts” panel hosted by the Biology of Breathing Research Trainees’ Hub.


Azome Therapeutics is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases, including acute lung injury, Acute Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.  The company’s lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.

Comments


bottom of page